Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2013
03/21/2013WO2012154975A3 Nitric oxide/cgmp pathway inhibition of vla-4 related cell adhesion
03/21/2013WO2012154009A3 Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases
03/21/2013WO2012153950A3 Method for preparing t-butyl 2-((4r,6s)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl)acetate
03/21/2013WO2012135592A3 Theranostic imaging agents and methods of use
03/21/2013WO2012118409A3 Spirocyclic cyclopropanoic amino acids and drugs based thereon
03/21/2013WO2012085648A9 Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
03/21/2013WO2011143872A9 Crystal form of (s)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparation method and use thereof
03/21/2013WO2011140000A3 Natural polymer blends for use in personal care products
03/21/2013WO2011087995A3 Nitro - imidazo - oxazine derivatives and their use in the treatment of mycobacterial infections
03/21/2013US20130074218 Method for optimising gene expression using synonymous codon optimisation
03/21/2013US20130074201 Cancer-specific genetic rearrangements
03/21/2013US20130072884 Transdermal compositions comprising an active agent layer and an active agent conversion layer
03/21/2013US20130072854 Microbubble complexes and methods of use
03/21/2013US20130072684 Treatment of t-cell mediated diseases
03/21/2013US20130072667 Use of rgm and its modulators
03/21/2013US20130072574 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
03/21/2013US20130072573 Process for preparing extra pure 2, 6-diisopropyl phenol
03/21/2013US20130072571 Evaporative cooling composition
03/21/2013US20130072570 Interomone Compositions and Their Use to Modify Behavior in Different Vertebrate Species
03/21/2013US20130072569 Retinoid replacements and opsin agonists and methods for the use thereof
03/21/2013US20130072568 Retinoid replacements and opsin agonists and methods for the use thereof
03/21/2013US20130072567 Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine
03/21/2013US20130072566 Antimicrobial compositions
03/21/2013US20130072565 Method of increasing cell proliferation by advanced wound dressings
03/21/2013US20130072564 Peptide and small molecule agonists of epha and their uses
03/21/2013US20130072563 Peracid and 2-hydroxy organic acid compositions and methods for sanitation and disease prevention
03/21/2013US20130072561 Methods for the treatment and prevention of age-related retinal dysfunction
03/21/2013US20130072560 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
03/21/2013US20130072558 Methods for the treatment and prevention of age-related retinal dysfunction
03/21/2013US20130072557 Methods for the treatment and prevention of age-related retinal dysfunction
03/21/2013US20130072556 Retinal derivatives and methods for the use thereof for the treatment of visual disorders
03/21/2013US20130072555 Compositions and methods for treating metabolic diseases
03/21/2013US20130072554 Novel Method For Delivery and Use of Isothiocyanates For Prophylaxis and/or Therapy of Bladder Cancer
03/21/2013US20130072553 Drugs, derivatives and analogs containing adamantane structures of new indication applications of anti-tumor
03/21/2013US20130072552 Crystalline hydrochloride salt of darunavir
03/21/2013US20130072551 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
03/21/2013US20130072550 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPalpha SECRETION AND IMROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS
03/21/2013US20130072549 Methods of treating cardiomyopathy
03/21/2013US20130072546 Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
03/21/2013US20130072545 MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
03/21/2013US20130072542 Piscine reovirus diagnostic compositions
03/21/2013US20130072541 Adeno-associated viral vector for exon skipping in a gene encoding a dispensible-domain protein
03/21/2013US20130072540 RNA interference of galectin-3 expression and methods of use thereof
03/21/2013US20130072539 Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand
03/21/2013US20130072537 Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
03/21/2013US20130072536 Pyrazole compounds that modulate hsp90 activity
03/21/2013US20130072535 Pyrazolecarboxamide derivatives and their use as microbiocides
03/21/2013US20130072534 Compositions comprising venlafaxine and celecoxib in the treatment of pain
03/21/2013US20130072533 Compounds with both analgesic and anti-hyperalgesic efficacy
03/21/2013US20130072532 Topical transdermal dexmedetomidine compositions and methods of use thereof
03/21/2013US20130072531 Solid dispersion comprising an anti-hiv agent
03/21/2013US20130072529 Pharmaceutical composition comprising aleglitazar
03/21/2013US20130072528 Methods for Treating HCV
03/21/2013US20130072527 Methods of using sustained release aminopyridine compositions
03/21/2013US20130072525 Nitrate and diazeniumdiolate derivatives of pioglitazone
03/21/2013US20130072522 Process for Making Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
03/21/2013US20130072520 Antibacterial agents
03/21/2013US20130072519 2-phenyl benzoylamides
03/21/2013US20130072517 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
03/21/2013US20130072516 Method of alcohol cessation and treatment
03/21/2013US20130072515 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
03/21/2013US20130072514 Sustained-Release Opioid Formulations and Methods of Use
03/21/2013US20130072513 COMBINATIONS OF BERBERINE, ARTEMISININ, Loperamide AND THEIR DERIVATIVES TO TREAT MALARIA, DIARRHEA, TRAVELERS' DIARRHEA, DYSENTERY, DENGUE FEVER, PARASITES, CHOLERA AND VIRUSES
03/21/2013US20130072512 Rifaximin ready-to-use suspension
03/21/2013US20130072511 Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
03/21/2013US20130072509 Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation
03/21/2013US20130072508 Solid pharmaceutical dosage form
03/21/2013US20130072507 Combination
03/21/2013US20130072506 6,8-disubstituted purine compositions
03/21/2013US20130072504 Crystalline forms of a purine derivative
03/21/2013US20130072503 Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
03/21/2013US20130072501 2,5-substituted oxazolopyrimidine derivatives
03/21/2013US20130072499 PIPERAZINE DERIVATIVES FOR BLOCKING Cav2.2 CALCIUM CHANNELS
03/21/2013US20130072498 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
03/21/2013US20130072496 Formulations containing pyridazine compounds
03/21/2013US20130072495 Fused bicyclic kinase inhibitors
03/21/2013US20130072494 Inhibitors of jun n-terminal kinase
03/21/2013US20130072493 N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS
03/21/2013US20130072492 Soluble guanylate cyclase activators
03/21/2013US20130072490 Polycyclic compounds as lysophosphatidic acid receptor antagonists
03/21/2013US20130072486 Pyrimidine cyclohexyl glucocorticoid receptor modulators
03/21/2013US20130072485 Soluble mtor complexes and modulators thereof
03/21/2013US20130072484 Tyrosine kinase inhibitors as anti-kinetoplastid and anti-apicomplexan agents
03/21/2013US20130072482 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same
03/21/2013US20130072481 mTOR SELECTIVE KINASE INHIBITORS
03/21/2013US20130072480 Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators
03/21/2013US20130072479 Heterocyclic compounds and uses thereof in the treatment of sexual disorders
03/21/2013US20130072478 N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl-amides as bace1 inhibitors
03/21/2013US20130072477 Treatment of parkinson's disease and enhancement of dopamine signal using pde 10 inhibitor
03/21/2013US20130072476 Novel parenteral carbamazepine formulation
03/21/2013US20130072475 Compositions and methods for the treatment of asthma and associated disorders
03/21/2013US20130072474 Treatment of dementia of alzheimer's type with masitinib
03/21/2013US20130072473 Compounds for treating protein folding disorders
03/21/2013US20130072472 Noribogaine salt ansolvates
03/21/2013US20130072470 Novel tricyclic compounds
03/21/2013US20130072469 Heteroaryl compounds and uses thereof
03/21/2013US20130072468 Substituted piperazines as cb1 antagonists
03/21/2013US20130072467 Nitrogen-containing heterocyclic compound
03/21/2013US20130072466 Composition containing placenta extracts
03/21/2013US20130072465 Novel betulinic acid derivatives with antiviral activity
1 ... 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 ... 7860